ASTRAZENECA PLC-SPONS ADR (AZN)       66.21  +0.04 (+0.06%)

66.21  +0.04 (+0.06%)

US0463531089 - ADR - After market: 66.7354 +0.53 (+0.79%)


Fundamental Rating

5

Overall AZN gets a fundamental rating of 5 out of 10. We evaluated AZN against 253 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of AZN get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, AZN is valued expensive at the moment.




Profitability

Profitability Rating

6

AZN has a Return On Assets of 2.16%. This is amongst the best returns in the industry. The industry average is -41.45%. AZN outperforms 86% of its industry peers.
AZN's Profit Margin of 4.52% is amongst the best of the industry. AZN does better than the industry average Profit Margin of -97.50%.

The Piotroski-F score of AZN is 7.00. This is a strong score and indicates good health and profitability for AZN.
AZN has a Return On Equity of 5.80%. This is below the industry average of 19.66%.
VS Industry

ROA (2.16%) VS Industry: 86% outperformed.

-1,292.14
111.39

ROE (5.8%) VS Industry: 27% outperformed.

1.38
176.97

Profit Margin (4.52%) VS Industry: 80% outperformed.

-53,337.68
1,968.82

Valuation

Valuation Rating

3

The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The Price/Earnings Ratio is 18.92, which indicates a rather expensive current valuation of AZN.
With a Forward Price/Earnings Ratio of 16.91, AZN is valued correctly.
With a price book ratio of 5.84, AZN is valued correctly.

AZN's Price/Earning Ratio is slightly more expensive than the industry average, which is at 13.52.
When comparing the price book ratio of AZN to the average industry price book ratio of 1.48, AZN is valued more expensive than its industry peers. 88% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of AZN to the average industry ratio of 3.45, AZN is valued more expensive than its industry peers. 88% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (18.92) VS Industry: 25% outperformed.

82.50
0.02

Price/Book (5.84) VS Industry: 12% outperformed.

309.96
0.10

Enterprise Value/ EBITDA (16.53) VS Industry: 12% outperformed.

246.53
0.01

Growth

Growth Rating

6

AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.50%, which is quite impressive.
Based on estimates for the next 5 years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.96% on average per year.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Revenue has grown by 37.60% in the past year. This is a very strong growth!

AZN shows quite a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 10.22% yearly.
AZN shows a small growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 4.14% yearly.
AZN is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 7.46% yearly.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS4.14% 15.13% 48.5% 28.94% 21.4% 20.31% 17.96%
Revenue10.22% 19.2% 37.6% 21.68% 13.05% 11.94% 7.46%

Health

Health Rating

4

AZN is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -0.52.
The Piotroski-F score of AZN is 7.00. This is a strong score and indicates good health and profitability for AZN.
An Altman-Z score of 2.77 indicates that AZN is not a great score, but indicates only limited risk for bankruptcy at the moment.
A Current Ratio of 0.81 indicates that AZN may have some problems paying its short term obligations.

Compared to an average industry Current Ratio of 3.52, AZN is worse placed to pay its short term obligations than its industry peers. 93% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.61 indicates that AZN may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 2.88, AZN is worse placed to pay its short term obligations than its industry peers. 91% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, AZN is requires more financing than its industry peers. 80% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (0.67) VS Industry: 20% outperformed.

59.36
0.00

Quick Ratio (0.61) VS Industry: 9% outperformed.

-2.73
76.82

Current Ratio (0.81) VS Industry: 7% outperformed.

0.09
76.82

Altman-Z (2.77) VS Industry: 75% outperformed.

-219.98
112.97

Dividend

Dividend Rating

4

AZN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has a Yearly Dividend Yield of 2.03%.
AZN's Dividend Yield is comparable with the S&P500 average which is at 2.47.

The dividend of AZN has a limited annual growth rate of 1.17%.
Compared to an average industry Dividend Yield of 2.79, AZN is paying slightly less dividend.
214.03% of the earnings are spent on dividend by AZN. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (2.03%) VS Industry: 27% outperformed.

0.69
7.31
AZN Daily chart

ASTRAZENECA PLC-SPONS ADR66.21

NASDAQ:AZN (11/28/2022, 6:37:46 PM)+0.04 (+0.06%)

After market: 66.7354 +0.53 (+0.79%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-10 2022-11-10/bmo Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 16.83%
Market Cap 205.19B Analysts 80
Valuation
PE 18.92 Fwd PE 16.91
PEG (NY) 0.65 PEG (5Y) 4.57
P/S 4.54 P/B 5.84
EV/EBITDA 16.53
Dividend
Dividend Yield 2.03% Dividend Growth 1.17%
DP 214.03% Ex-Date 08-11 2022-08-11 (0.465)
Growth
EPS 1Y 48.5% EPS 3Y 15.13%
EPS 5Y 4.14% EPS growth Q2Q 54.63%
EPS Next Y 28.94% EPS Next 2Y 21.4%
EPS Next 3Y 20.31% EPS Next 5Y 17.96%
Revenue growth 1Y 37.6% Revenue growth 3Y 19.2%
Revenue growth 5Y 10.22% Revenue growth Q2Q 11.31%
Revenue Next Year 21.68% Revenue Next 2Y 13.05%
Revenue Next 3Y 11.94% Revenue Next 5Y 7.46%
Health
Current Ratio 0.81 Quick Ratio 0.61
Altman-Z 2.77 F-Score 7
Debt/Equity 0.67 WACC 8.03%
ROIC/WACC 13.32
Profitability
ROA 2.16% ROE 5.8%
ROICexgc 106.93% ROIC 8.76%
PM 4.52% OM 16.9%
Asset Turnover 0.48

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA